Published in AIDS Vaccine Week, August 30th, 2004
The U.S. Food and Drug Administration (FDA) has reviewed Starpharma's interim study results and has given clearance to proceed using the highest dosage concentrate planned for this study.
This next stage involves administration of VivaGel containing 3.0% of the active dendrimer ingredient, SPL7013, and placebo gel to a group of healthy women. This is the continuation of the U.S. IND Study No. SPL7013-001, investigating escalating formulation strengths of VivaGel. The study is the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.